Design Therapeutics, Inc. (DSGN) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$14.10
Price Target
$16.75
Target Range
$14.00 — $20.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-11.6x
Forward PEG—
Implied Growth-22.2%
Median Target$16.50
Analyst Spread35.8%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$14
-0.7%
Consensus
$17
+18.8%
Bull Case
$20
+41.8%
DSGN Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Design Therapeutics, Inc. (DSGN) has a Wall Street consensus price target of $16.75, based on estimates from 6 covering analysts. With the stock currently trading at $14.10, this represents a potential upside of +18.8%. The company has a market capitalization of $881M.
Analyst price targets range from a low of $14.00 to a high of $20.00, representing a 36% spread in expectations. The median target of $16.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, DSGN trades at a trailing P/E of -11.6x. Analysts expect EPS to grow -22.2% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+99.8%
Avg Forward P/E229.1x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 FULCFulcrum Therapeutics, Inc. | $372M | $6.88 | $20.67 | +200.4% | Buy | — | 16 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $103.18 | -1.6% | Buy | 582.8x | 41 |
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $2.6B | $20.66 | $35.50 | +71.8% | Buy | 77.6x | 12 |
 BEAMBeam Therapeutics Inc. | $3.2B | $31.47 | $40.83 | +29.7% | Buy | — | 27 |
 EDITEditas Medicine, Inc. | $297M | $3.03 | $6.00 | +98.0% | Buy | — | 25 |
 CRSPCRISPR Therapeutics AG | $5.1B | $52.42 | $63.00 | +20.2% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.71 | $20.88 | +52.3% | Buy | — | 39 |
 PRMEPrime Medicine, Inc. | $562M | $3.12 | $17.25 | +453.8% | Buy | — | 9 |
 ILMNIllumina, Inc. | $21.1B | $138.71 | $147.38 | +6.3% | Buy | 26.8x | 50 |
Upside Potential Comparison
PRMEFULCEDITARQTIMVTNTLABEAMCRSPSee DSGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DSGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DSGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDSGN — Frequently Asked Questions
Quick answers to the most common questions about buying DSGN stock.
What is the DSGN stock price target for 2026?
Design Therapeutics, Inc. (DSGN) has a consensus 12-month price target of $16.75, implying 18.8% upside from $14.1. The 6 analysts covering DSGN see moderate appreciation potential.
Is DSGN a buy, sell, or hold?
DSGN has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $16.75 implies 18.8% upside from current levels.
Is DSGN stock overvalued or undervalued?
DSGN's current price is $14.1 with a consensus target of $16.75 (18.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can DSGN stock go?
The most bullish Wall Street analyst has a price target of $20 for DSGN, while the most conservative target is $14. The consensus of $16.75 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover DSGN stock?
DSGN is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the DSGN stock forecast?
The 12-month DSGN stock forecast based on 6 Wall Street analysts shows a consensus price target of $16.75, with estimates ranging from $14 (bear case) to $20 (bull case). The median consensus rating is "Buy".
Should I buy DSGN stock?
Wall Street analysts are optimistic on DSGN, with a "Buy" consensus rating and $16.75 price target (18.8% upside). 3 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do DSGN price targets vary so much?
DSGN analyst price targets range from $14 to $20, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16.75 consensus represents the middle ground.